Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT

Overview

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease. And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of inflammatory bowel disease than 18F-FDG PET/CT.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 1, 2022

Detailed Description

Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn's disease(CD).CD is an autoimmune condition resulting in chronic gut inflammation that can be complicated by intestinal fibrosis and stricture formation. Ulcerative colitis is characterized by recurring episodes of inflammation limited to the mucosal layer of the colon. It commonly involves the rectum and may extend in a proximal and continuous fashion to involve other parts of the colon. Studies identified FAP to be overexpressed in uninflamed strictures compared with nonstrictured colonic regions in biopsies taken from Crohn's disease patients. But preliminary studies showed FAP was not overexpressed in colonic biopsies taken from healthy individuals or individuals with ulcerative colitis.68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and inflammation. Recently we have published an article of the application of 68Ga-FAPI in IgG4-related disease which showed it was more sensitive than FDG in detecting a certain type of inflammations. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of IBD than 18F-FDG PET/CT.

Interventions

  • Drug: 68Ga-FAPI
    • Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of inflammatory bowel disease by PET/CT.

Arms, Groups and Cohorts

  • Experimental: 68Ga-FAPI, PET/CT
    • Inject 68Ga-FAPI and then perform PET/CT scan.

Clinical Trial Outcome Measures

Primary Measures

  • Diagnostic value
    • Time Frame: through study completion, an average of 1 year
    • Sensitivity and Specificity of 68Ga-FAPI PET/CT for inflammatory bowel disease in comparison with 18F-FDG PET/CT

Secondary Measures

  • Metabolic parameters
    • Time Frame: through study completion, an average of 1 year
    • Total Lesion Glycolysis (TLG) of bowel lesions are measured on 68Ga-FAPI PET/CT.
  • FAPI expression and SUV
    • Time Frame: through study completion, an average of 1 year
    • Correlation between FAPI expression and SUV in PET
  • Disease burden assessement
    • Time Frame: through study completion, an average of 1 year
    • Correlation between Total Lesion Glycolysis (TLG) of bowel lesions assessed on 68Ga-FAPI PET/CT and clinical parameters for inflammatory bowel disease
  • therapy response
    • Time Frame: through study completion, an average of 1 year
    • Decrease of Total Lesion Glycolysis (TLG) on 68Ga-FAPI PET/CT after therapy

Participating in This Clinical Trial

Inclusion Criteria

  • suspected or confirmed untreated inflammatory bowel disease patients; – 18F-FDG PET/CT within two weeks; – signed written consent. Exclusion Criteria:

  • pregnancy; – breastfeeding; – known allergy against FAPI – any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking Union Medical College Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yaping Luo, MD, Principal Investigator, Peking Union Medical College Hospital
  • Overall Contact(s)
    • Yaping Luo, MD, 86-10-69155513, luoyaping@live.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.